Exelixis (EXEL) Tops Q3 EPS by 13c, Tops on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Exelixis (EXEL) PT Raised to $29 at Stephens
October 30, 2024 6:27 AM EDTStephens analyst Sudan Loganathan raised the price target on Exelixis (NASDAQ: EXEL) to $29.00 (from $23.00) while maintaining a Equal Weight rating.
The analyst comments "EXEL reported 3Q24 financial results yesterday (10/29/2024) after market close and provided regulatory and business updates. Key highlights on the... More
Exelixis (EXEL) PT Raised to $38 at Citi
October 30, 2024 5:47 AM EDTCiti analyst David Lebowitz raised the price target on Exelixis (NASDAQ: EXEL) to $38.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Exelixis reported 3Q24 financial results, beating consensus on top-line revenue and GAAP EPS due to continued strength of cabozantinib. Total... More
